

## **VEGFC (VEGF3) Antibody (Center M263)**

Purified Rabbit Polyclonal Antibody (Pab)
Catalog # AP2042C

## **Specification**

# VEGFC (VEGF3) Antibody (Center M263) - Product Information

Application WB, IHC-P,E **Primary Accession** P49767 Reactivity Human Host Rabbit Clonality Polyclonal Isotype Rabbit Iq Calculated MW 46883 Antigen Region 248-277

VEGFC (VEGF3) Antibody (Center M263) - Additional Information

#### **Gene ID 7424**

#### **Other Names**

Vascular endothelial growth factor C, VEGF-C, Flt4 ligand, Flt4-L, Vascular endothelial growth factor-related protein, VRP, VEGFC

#### Target/Specificity

This VEGFC (VEGF3) antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 248-277 amino acids from the Central region of human VEGFC (VEGF3).

## Dilution


WB~~1:1000 IHC-P~~1:10~50

#### **Format**


Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.

### Storage

Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.



Western blot analysis of VEGF3 Antibody (Center) polyclonal antibody(Cat.#AP2042c)(arrow). 293 cell lysates (2 ug/lane) either nontransfected (Lane 1) or transiently transfected with the VEGF3 gene (Lane 2) (Origene Technologies).



Formalin-fixed and paraffin-embedded human lung carcinoma tissue reacted with VEGF3 Antibody (Center M263)(Cat.#AP2042c), which was peroxidase-conjugated to the secondary





Tel: 858.875.1900 Fax: 858.622.0609

#### **Precautions**

VEGFC (VEGF3) Antibody (Center M263) is for research use only and not for use in diagnostic or therapeutic procedures.

VEGFC (VEGF3) Antibody (Center M263) - Protein Information

#### Name VEGFC

#### **Function**

Growth factor active in angiogenesis, and endothelial cell growth, stimulating their proliferation and migration and also has effects on the permeability of blood vessels. May function in angiogenesis of the venous and lymphatic vascular systems during embryogenesis, and also in the maintenance of differentiated lymphatic endothelium in adults. Binds and activates KDR/VEGFR2 and FLT4/VEGFR3 receptors.

## **Cellular Location** Secreted.

#### **Tissue Location**

Spleen, lymph node, thymus, appendix, bone marrow, heart, placenta, ovary, skeletal muscle, prostate, testis, colon and small intestine and fetal liver, lung and kidney, but not in peripheral blood lymphocyte

# VEGFC (VEGF3) Antibody (Center M263) -**Protocols**

Provided below are standard protocols that you may find useful for product applications.

- Western Blot
- Blocking Peptides
- Dot Blot
- Immunohistochemistry
- Immunofluorescence
- Immunoprecipitation
- Flow Cytomety
- Cell Culture

## VEGFC (VEGF3) Antibody (Center M263) - Citations

Podoplanin Expression Correlates with Disease Progression in Mycosis Fungoides.

antibody, followed by DAB staining. This data demonstrates the use of this antibody for immunohistochemistry; clinical relevance has not been evaluated.

# VEGFC (VEGF3) Antibody (Center M263) -**Background**

VEGF3 is a member of the platelet-derived growth factor/vascular endothelial growth factor (PDGF/VEGF) family, is active in angiogenesis and endothelial cell growth, and can also affect the permeability of blood vessels. This secreted protein undergoes a complex proteolytic maturation, generating multiple processed forms which bind and activate VEGFR-3 receptors. Only the fully processed form can bind and activate VEGFR-2 receptors. This protein is structurally and functionally similar to vascular endothelial growth factor D.

# VEGFC (VEGF3) Antibody (Center M263) -References

Byeon, J.S., et al., J. Gastroenterol. Hepatol. 19(6):648-654 (2004).

Su, J.L., et al., Cancer Res. 64(2):554-564 (2004).

Yan, C., et al., World J. Gastroenterol. 10(6):783-790 (2004).

Hsieh, C.Y., et al., J. Biomed. Sci. 11(2):249-259 (2004).

Liu, X.E., et al., World J. Gastroenterol. 10(3):352-355 (2004).